HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetic Marketplace News: Fenty Beauty; Camel Milk; CVS Vending Machines; More

This article was originally published in The Rose Sheet

Executive Summary

Launched in partnership with LVMH incubator Kendo Brands, Rihanna's 91-SKU makeup line is designed to accommodate traditionally hard-to-match skin tones. More cosmetic marketplace news in brief.

You may also be interested in...



Rihanna’s Fenty Was Top-Earning Celebrity Beauty Brand In 2021

Pop star Rihanna’s Fenty Beauty brand accounted for more than a third of global celebrity beauty brand sales in 2021, finds sports betting site OLBG.com. Jessica Alba’s Honest Company and Kylie Jenner’s Kylie Cosmetics finished second and third, respectively.

CoverGirl Introduces Full Spectrum Makeup As ‘Fenty Effect’ Continues To Resonate

“Understanding that inclusivity goes far beyond shade ranges, Full Spectrum was developed with the unique shade AND skin needs of multicultural women in mind,” according to a Coty/CoverGirl rep. The line is available now at Ulta.com, with a wider rollout planned for February 2019.

Revlon Highlights Flesh Beauty Launch, China Momentum In Q2 Report

The firm remains in brand- and digital-building mode, but it’s seeing marked progress while looking forward to planned H2 innovations and the impact of its recently introduced Flesh line of “inclusive” color cosmetics. Opportunity beckons in China, where Revlon’s second-quarter sales grew 46%.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel